Advisor OS’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,228
Closed -$520K 615
2025
Q4
$520K Sell
10,228
-655
-6% -$33.5K 0.04% 275
2025
Q3
$604K Buy
10,883
+1,885
+21% +$110K 0.05% 225
2025
Q2
$621K Buy
8,998
+1,143
+15% +$77.7K 0.06% 218
2025
Q1
$545K Sell
7,855
-1,131
-13% -$93.4K 0.06% 223
2024
Q4
$773K Sell
8,986
-4,647
-34% -$503K 0.09% 153
2024
Q3
$1.62M Sell
13,633
-339
-2% -$45.2K 0.16% 107
2024
Q2
$1.99M Buy
13,972
+82
+0.6% +$10.9K 0.22% 87
2024
Q1
$1.78M Buy
13,890
+758
+6% +$90.2K 0.2% 91
2023
Q4
$1.36M Sell
13,132
-202
-2% -$20K 0.18% 99
2023
Q3
$1.21M Buy
13,334
+2,964
+29% +$261K 0.18% 102
2023
Q2
$839K Buy
10,370
+690
+7% +$56.4K 0.14% 149
2023
Q1
$770K Sell
9,680
-2,710
-22% -$192K 0.18% 133
2022
Q4
$838K Buy
12,390
+1,616
+15% +$94.7K 0.22% 104
2022
Q3
$537K Buy
10,774
+732
+7% +$39.2K 0.16% 126
2022
Q2
$561K Buy
10,042
+1,396
+16% +$77.5K 0.16% 133
2022
Q1
$480K Buy
+8,646
New +$444K 0.14% 151

Other funds holding NVO

Advisor OS's NVO Position: Q1 2026 in Review

Advisor OS sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 10,228 shares — an estimated $520K sold.

Advisor OS first reported a position in NVO in Q1 2022 and held it in 16 quarters. The position peaked at $1.99M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Advisor OS reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Advisor OS sold 10,228 Novo Nordisk shares in Q1 2026, an estimated $520K.
  • Advisor OS first reported a position in Novo Nordisk in Q1 2022 and held it in 16 quarters.
  • Advisor OS's Novo Nordisk position peaked at $1.99M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Advisor OS's 13F filing for Q1 2026, filed 8 May 2026.